Louise E. Purton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Louise E. Purton has a total of 406 co-authors. Here are the top co-authors by number of shared publications:
- Carl R. Walkley
Centre for Innate Immunity and Infectious Disease, Hudson Institute of Medical Research 1 , Clayton, Victoria, Australia
31 shared publications - Alanna Claire Green
Mellanby Centre for Musculoskeletal Research and Healthy Lifespan Institute, School of Medicine and Population Health, Faculty of Health, University of Sheffield, Sheffield, UK
9 shared publications - Natalie A. Sims
St. Vincent’s Institute of Medical Research
9 shared publications - Alistair M. Chalk
St Vincent’s Institute of Medical Research, Fitzroy, Australia
8 shared publications Meaghan Wall
Department of Medicine at St. Vincent’s Hospital, The University of Melbourne
8 shared publicationsGavin Tjin
Stem Cell Regulation Unit, St. Vincent’s Institute of Medical Research, Fitzroy, VIC 3065, Australia
7 shared publications
Latest Publications
- 27 March 2026
- Published by Elsevier in Experimental Hematology
- Vol. 158, 105422
Highlighting the contributions of Professor T. Ray Bradley to ISEH and the field of Experimental Hematology
- 27 March 2026
- Published by Elsevier in Experimental Hematology
- Vol. 158, 105422
Highlighting the contributions of Professor T. Ray Bradley to ISEH and the field of Experimental Hematology
- Open Access
ADAR1p150 RNA binding, independent of A-to-I RNA editing, buffers immunogenicity from the tonic type I IFN induced transcriptome in vivo
ADAR1 edits adenosine to inosine (A-to-I) in double-stranded RNA to prevent MDA5 sensing of cellular transcripts, its key physiological role. However, editing-independent functions of ADAR1 remain poorly understood. Using a series of Adar1 mutant mice rescued by loss of MDA5 and PKR, we investigated isoform-specific, editing-independent roles of ADAR1 in vivo . We found that the cytoplasmic ADAR1p150 isoform is essential for maintaining peripheral T cell numbers and differentiation of hematopoietic stem and progenitor cells (HSPCs). In bone marrow transplants, ADAR1p150 protein, but not its editing activity, was crucial for T cell regeneration and HSPC repopulation, demonstrating a cell-intrinsic function in hematopoiesis. Experiments with IFNβ-treatment of purified HSPCs in vitro and in vivo IFNAR1 neutralization revealed hypersensitivity to tonic type I interferon (IFN) in the absence of ADAR1p150. Using cell lines, we demonstrate that type I IFN activates the OAS-RNaseL pathway, leading to cell death. This study shows that tonic type I IFN induces immunogenic cellular RNAs in sterile conditions. ADAR1p150 suppresses immune sensing of self-dsRNAs through both editing-dependent (MDA5) and editing-independent (PKR, OAS-RNaseL) mechanisms. Thus, ADAR1p150 protein levels and activity combine to set the threshold for tolerance to self-derived dsRNAs.
Open AccessADAR1p150 RNA binding, independent of A-to-I RNA editing, buffers immunogenicity from the tonic type I IFN induced transcriptome in vivo
ADAR1 edits adenosine to inosine (A-to-I) in double-stranded RNA to prevent MDA5 sensing of cellular transcripts, its key physiological role. However, editing-independent functions of ADAR1 remain poorly understood. Using a series of Adar1 mutant mice rescued by loss of MDA5 and PKR, we investigated isoform-specific, editing-independent roles of ADAR1 in vivo . We found that the cytoplasmic ADAR1p150 isoform is essential for maintaining peripheral T cell numbers and differentiation of hematopoietic stem and progenitor cells (HSPCs). In bone marrow transplants, ADAR1p150 protein, but not its editing activity, was crucial for T cell regeneration and HSPC repopulation, demonstrating a cell-intrinsic function in hematopoiesis. Experiments with IFNβ-treatment of purified HSPCs in vitro and in vivo IFNAR1 neutralization revealed hypersensitivity to tonic type I interferon (IFN) in the absence of ADAR1p150. Using cell lines, we demonstrate that type I IFN activates the OAS-RNaseL pathway, leading to cell death. This study shows that tonic type I IFN induces immunogenic cellular RNAs in sterile conditions. ADAR1p150 suppresses immune sensing of self-dsRNAs through both editing-dependent (MDA5) and editing-independent (PKR, OAS-RNaseL) mechanisms. Thus, ADAR1p150 protein levels and activity combine to set the threshold for tolerance to self-derived dsRNAs.
- 11 October 2025
- Published by Elsevier in Experimental Hematology
- Vol. 151, 105263
Honoring giants in hematopoietic stem and progenitor cell biology
- 11 October 2025
- Published by Elsevier in Experimental Hematology
- Vol. 151, 105263
Honoring giants in hematopoietic stem and progenitor cell biology
- Open Access
- 15 August 2024
- Published by Wolters Kluwer Health in Blood Science
- Vol. 6 (4) , e00202
Adult megakaryopoiesis: when taking a short-cut results in a different final destination
- 15 August 2024
- Published by Wolters Kluwer Health in Blood Science
- Vol. 6 (4) , e00202
Open AccessAdult megakaryopoiesis: when taking a short-cut results in a different final destination
- Open Access
Dysregulated expression of Hoxa1 isoforms in hematopoietic stem and progenitor cells causes myelodysplastic syndromes
The homeobox gene, Hoxa1 , has two different isoforms generated by alternative splicing: a full-length homeodomain-containing Hoxa1 ( Hoxa1-FL ), and a truncated Hoxa1 ( Hoxa1-T ), that lacks the homeodomain. The effects of the distinct Hoxa1 isoforms in hematopoiesis have not been investigated. Oncoretroviral studies revealed that Hoxa1-T acts in a dominant negative manner, regulating transcriptionally active Hoxa1. Oncoretroviral overexpression of wildtype Hoxa1 ( WT-Hoxa1 ), which generates both Hoxa1 isoforms, in murine hematopoietic stem and progenitor cells (HSPCs) perturbed hematopoiesis, resulting in transplantable myelodysplastic syndromes (MDS) in mice. Overexpression of a mutated Hoxa1 cDNA ( MUT-Hoxa1 ) that generates Hoxa1-FL , but not Hoxa1-T , led to a more severe MDS that transformed to secondary acute myeloid leukemia (sAML). DNA damage repair pathways were downregulated in Hoxa1 -overexpressing hematopoietic progenitor cells, accompanied by increased γH2AX foci. In silico analyses revealed that CD34+ cells from approximately 50% of patients with MDS had elevated HOXA1-FL expression. Conditional knock-in WT-Hoxa1 and MUT-Hoxa1 mice were generated and had features of pre-MDS, developing altered hematopoiesis within 4 months of Hoxa1 isoform overexpression in HSPCs. HSPCs were significantly reduced in all knock-in mice, accompanied by significantly increased apoptosis in WT-Hoxa1 HSPCs. Healthy wildtype recipients transplanted with bone marrow cells from Hoxa1 knock-in mice developed trilineage MDS, with Hoxa1 isoform and gene dosage dependent phenotypes. Collectively our data identify a role for HOXA1 in the pathogenesis of MDS. Our Hoxa1 mouse models capture different stages of progression of disease from pre-MDS to MDS to sAML and provide novel, clinically relevant tools to study MDS. Key points: HOXA1 is upregulated in approximately 50% of MDS patient CD34+ BM cells, highlighting a potential role for HOXA1 in the pathogenesis of MDS. Dysregulated expression of Hoxa1 isoforms in murine hematopoietic stem and progenitor cells predisposes mice to pre-MDS and MDS.
Open AccessDysregulated expression of Hoxa1 isoforms in hematopoietic stem and progenitor cells causes myelodysplastic syndromes
The homeobox gene, Hoxa1 , has two different isoforms generated by alternative splicing: a full-length homeodomain-containing Hoxa1 ( Hoxa1-FL ), and a truncated Hoxa1 ( Hoxa1-T ), that lacks the homeodomain. The effects of the distinct Hoxa1 isoforms in hematopoiesis have not been investigated. Oncoretroviral studies revealed that Hoxa1-T acts in a dominant negative manner, regulating transcriptionally active Hoxa1. Oncoretroviral overexpression of wildtype Hoxa1 ( WT-Hoxa1 ), which generates both Hoxa1 isoforms, in murine hematopoietic stem and progenitor cells (HSPCs) perturbed hematopoiesis, resulting in transplantable myelodysplastic syndromes (MDS) in mice. Overexpression of a mutated Hoxa1 cDNA ( MUT-Hoxa1 ) that generates Hoxa1-FL , but not Hoxa1-T , led to a more severe MDS that transformed to secondary acute myeloid leukemia (sAML). DNA damage repair pathways were downregulated in Hoxa1 -overexpressing hematopoietic progenitor cells, accompanied by increased γH2AX foci. In silico analyses revealed that CD34+ cells from approximately 50% of patients with MDS had elevated HOXA1-FL expression. Conditional knock-in WT-Hoxa1 and MUT-Hoxa1 mice were generated and had features of pre-MDS, developing altered hematopoiesis within 4 months of Hoxa1 isoform overexpression in HSPCs. HSPCs were significantly reduced in all knock-in mice, accompanied by significantly increased apoptosis in WT-Hoxa1 HSPCs. Healthy wildtype recipients transplanted with bone marrow cells from Hoxa1 knock-in mice developed trilineage MDS, with Hoxa1 isoform and gene dosage dependent phenotypes. Collectively our data identify a role for HOXA1 in the pathogenesis of MDS. Our Hoxa1 mouse models capture different stages of progression of disease from pre-MDS to MDS to sAML and provide novel, clinically relevant tools to study MDS. Key points: HOXA1 is upregulated in approximately 50% of MDS patient CD34+ BM cells, highlighting a potential role for HOXA1 in the pathogenesis of MDS. Dysregulated expression of Hoxa1 isoforms in murine hematopoietic stem and progenitor cells predisposes mice to pre-MDS and MDS.
- Open Access
- 23 October 2022
- Published by Elsevier in Experimental Hematology
- Vol. 116, 1-14
Adult murine hematopoietic stem cells and progenitors: an update on their identities, functions, and assays
- 23 October 2022
- Published by Elsevier in Experimental Hematology
- Vol. 116, 1-14
Open AccessAdult murine hematopoietic stem cells and progenitors: an update on their identities, functions, and assays
- Open Access
- 5 July 2022
- Published by Wiley in Immunology & Cell Biology
- Vol. 100 (9) , 674-678
Gender inequities in medical research funding is driving an exodus of women from Australian STEMM academia
Universally, women are under‐represented in senior academic leadership in science, technology, engineering, maths and medicine (STEMM). Successful funding outcomes are a critical point in career progression, to continue both a scientist’s research but also for their retention within the STEMM workforce. A common explanation for the lower success rate of women in securing funding is that fewer women apply for funding. However, this does not adequately explain the gender inequities in funding outcomes, both in terms of fewer funded applications and also of reduced funding awarded per grant, resulting in less overall success. Gendered funding outcomes occur within academic institutions and peak funding bodies due to historical, systemic conscious and unconscious biases during peer review. As a cumulative bias over a woman’s research career, this results in women being under‐represented in STEMM and the loss of their contributions to medical research, reducing innovation through a lack of diverse workforces.
- 5 July 2022
- Published by Wiley in Immunology & Cell Biology
- Vol. 100 (9) , 674-678
Open AccessGender inequities in medical research funding is driving an exodus of women from Australian STEMM academia
Universally, women are under‐represented in senior academic leadership in science, technology, engineering, maths and medicine (STEMM). Successful funding outcomes are a critical point in career progression, to continue both a scientist’s research but also for their retention within the STEMM workforce. A common explanation for the lower success rate of women in securing funding is that fewer women apply for funding. However, this does not adequately explain the gender inequities in funding outcomes, both in terms of fewer funded applications and also of reduced funding awarded per grant, resulting in less overall success. Gendered funding outcomes occur within academic institutions and peak funding bodies due to historical, systemic conscious and unconscious biases during peer review. As a cumulative bias over a woman’s research career, this results in women being under‐represented in STEMM and the loss of their contributions to medical research, reducing innovation through a lack of diverse workforces.
- Open Access
- 18 May 2021
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 5 (10) , e10516
From the niche to malignant hematopoiesis and back: reciprocal interactions between leukemia and the bone marrow microenvironment
The bone marrow microenvironment (BMME) regulates hematopoiesis through a complex network of cellular and molecular components. Hematologic malignancies reside within, and extensively interact with, the same BMME. These interactions consequently alter both malignant and benign hematopoiesis in multiple ways, and can encompass initiation of malignancy, support of malignant progression, resistance to chemotherapy, and loss of normal hematopoiesis. Herein, we will review supporting studies for interactions of the BMME with hematologic malignancies and discuss challenges still facing this exciting field of research. © 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
- 18 May 2021
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 5 (10) , e10516
Open AccessFrom the niche to malignant hematopoiesis and back: reciprocal interactions between leukemia and the bone marrow microenvironment
The bone marrow microenvironment (BMME) regulates hematopoiesis through a complex network of cellular and molecular components. Hematologic malignancies reside within, and extensively interact with, the same BMME. These interactions consequently alter both malignant and benign hematopoiesis in multiple ways, and can encompass initiation of malignancy, support of malignant progression, resistance to chemotherapy, and loss of normal hematopoiesis. Herein, we will review supporting studies for interactions of the BMME with hematologic malignancies and discuss challenges still facing this exciting field of research. © 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.